Dr. Tripathy on Treatment De-Escalation in HER2+ Breast Cancer

Video

In Partnership With:

Debu Tripathy, MD, discusses treatment de-escalation in HER2-positive breast cancer.

Debu Tripathy, MD, professor of medicine and chair of the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses treatment de-escalation in HER2-positive breast cancer.

Patients with clinical stage I HER2-positive breast cancer may be eligible for de-escalated dosing of weekly paclitaxel and trastuzumab (Herceptin), says Tripathy.

Prior to de-escalati​on, patients will typically undergo up​-front surgery to confirm that their disease is not being up​staged​, says Tripathy.

If the patient has confirmed early-stage disease, or the​ir tumor is under 3 cm, therapy de-escalation can be considered per data from the phase 2 APT trial, explains Tripathy.

The field is ​currently awaiting ​the randomized data from the ​phase 2 ATEMPT trial to determine whether ado-trastuzumab emtansine (T-DM1; Kadcyla) could be de-escalated, Tripathy concludes.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Video 1 - "HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification "